IOLCP Q3 FY26 PBT Up 39% YoY to ₹38.8 Cr on 10.9% Revenue Growth
IOL Chemicals and Pharmaceuticals Limited reported Q3 FY26 standalone revenue of ₹580.4 crore, up 10.9% YoY. PBT surged 39.3% to ₹38.8 crore, with margins expanding. The Pharmaceuticals segment revenue grew 18% YoY, contributing 61% to total revenue. The company aims to expand in regulated markets and enhance R&D.
The results show positive financial performance with growth in key metrics and strategic focus on future expansion, which is moderately impactful for investors.
The company reported strong year-on-year growth in revenue, EBITDA, and PBT, along with margin expansion, indicating a positive financial performance.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has announced its financial results for the quarter and nine months ended December 31, 2025. The company reported a standalone revenue from operations of ₹580.4 crore for Q3 FY26, marking a 10.9% year-on-year increase from ₹523.3 crore in Q3 FY25. EBITDA for the quarter rose by 22.8% to ₹62.6 crore, with an expansion in EBITDA margin by 102 basis points to 10.7%. Profit Before Tax (PBT) before exceptional items grew by a significant 39.3% to ₹38.8 crore, compared to ₹27.8 crore in the same period last year. The PBT margin also improved by 134 basis points to 6.6%.
For the nine-month period ended December 31, 2025, IOLCP's revenue from operations stood at ₹1,699.6 crore, up 9.6% from ₹1,551.4 crore in 9M FY25. EBITDA for the nine months increased by 24.8% to ₹196.1 crore, and PBT grew by 34.2% to ₹124.8 crore.
Mr. Vikas Gupta, Joint Managing Director, commented that Q3 FY26 was a resilient quarter characterized by double-digit revenue growth and margin expansion. The Pharmaceuticals segment was a key growth driver, with revenue increasing by 18% year-on-year, and its share in overall revenue increased from 57% to 61%. EBIT from Pharmaceuticals grew by 32% YoY. The Chemicals segment also showed strong performance, with EBIT growing by 37% YoY due to optimal capacity utilization and efficiency gains.
Looking ahead, the company plans to focus on expanding its presence in regulated markets, strengthening its new product pipeline, deepening backward integration, and enhancing R&D capabilities to sustain growth and deliver long-term value.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.